Accéder au contenu
Merck

SML0425

Caspofungin diacetate

≥97% (HPLC), powder, cell wall synthesis inhibitor

Synonyme(s) :

1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C52H88N10O15 · 2C2H4O2
Numéro CAS:
179463-17-3
Poids moléculaire :
1213.42
UNSPSC Code:
51283107
PubChem Substance ID:
329825420
NACRES:
NA.77

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

Caspofungin diacetate, ≥97% (HPLC)

SMILES string

CC([O-])=O.CC([O-])=O.CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCC[NH3+])NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c4ccc(O)cc4)[C@H](O)CC[NH3+]

InChI

1S/C52H88N10O15.2C2H4O2/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72;2*1-2(3)4/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75);2*1H3,(H,3,4)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-;;/m0../s1

InChI key

OGUJBRYAAJYXQP-IJFZAWIJSA-N

assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

H2O: 15 mg/mL (clear solution)

shipped in

wet ice

storage temp.

−20°C

Quality Level

100

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application

Caspofungin diacetate has been used:

  • in an antifungal susceptibility test
  • as a standard antifungal for valproic acid (VPA)-synergy assessment
  • to treat Cryptococcus neoformans strain B3501 to study natural killer (NK) cell killing of Cryptococcus in the presence of β-1,3-glucan

Biochem/physiol Actions

Caspofungin is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthase which is required for cell wall synthesis.
Caspofungin is an echinocandin antifungal that inhibits 1,3-β-D-glucan synthase, which is required for cell wall synthesis, thereby disturbing the integrity of the fungal cell wall.
Caspofungin, aechinocandin, a lipophilic antifungal drug, and α β-1,3-D-glucan synthesis antagonist, are used in fungal cell wall biosynthesis research to study the role of β-1,3-D-glucans in cell wall integrity and fungal survival under various environmental and chemical stresses. Caspofungin is used to treat esophageal candidiasis, candida infections, febrile neutropenia, invasive candidiasis, and invasive aspergillosis.

General description

Caspofungin belongs to the echinocandins class of drugs. This drug has a limited α-phase half-life (t 1/2) of one to two hours (volume of distribution of 9.7L) and a β-phase t 1/2 of nine to 11 hours.

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000436940
0000436940
0000348332
0000348335
0000342542

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Sarah R Beattie et al.
mSphere, 7(3), e0016322-e0016322 (2022-05-05)
There is an urgent need for new antifungals to treat cryptococcal meningoencephalitis, a leading cause of mortality in people living with HIV/AIDS. An important aspect of antifungal drug development is the validation of targets to determine whether they are required
Joseph Meletiadis et al.
Antimicrobial agents and chemotherapy, 51(6), 2053-2064 (2007-03-28)
Triple antifungal combinations are used against refractory invasive aspergillosis without an adequate understanding of their pharmacodynamic interactions. We initially studied the in vitro triple combination of voriconazole, amphotericin B, and caspofungin against Aspergillus fumigatus, A. flavus, and A. terreus by
Liping Xiong et al.
mSphere, 9(7), e0037224-e0037224 (2024-07-09)
Iron acquisition is critical for pathogens to proliferate during invasive infection, and the human fungal pathogen Candida albicans is no exception. The iron regulatory network, established in reference strain SC5314 and derivatives, includes the central player Sef1, a transcription factor
Timothy Cairns et al.
STAR protocols, 3(4), 101883-101883 (2023-01-04)
This protocol describes procedures for quantifying Aspergillus niger growth in both solid and liquid culture. Firstly, by comparing radial growth between mutant and progenitor isolates on solid agar supplemented with sublethal stressors, susceptibility coefficients can be calculated. Secondly, analysis of
Esther Sheba et al.
The American journal of tropical medicine and hygiene, 108(2), 377-383 (2022-12-27)
This study describes the microbiological and histopathological features of patients with COVID-19-associated rhino-orbital mucormycosis (ROM) seen at the L V Prasad Eye Institute between May and August 2021. Diagnosed clinically and radiologically, 24 patients with ROM were included in the
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique